Manley P - Search Results

1

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.

Cross NC, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM. Cross NC, et al. Among authors: manley p. Leukemia. 2008 Nov;22(11):1975-89. doi: 10.1038/leu.2008.231. Leukemia. 2008. PMID: 19002192 No abstract available.

2

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs.

White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP. White DL, et al. Among authors: manley pw. Blood. 2007 Apr 15;109(8):3609-10. doi: 10.1182/blood-2006-11-058032. Blood. 2007. PMID: 17409347 Free article. No abstract available.

3

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.

Verstovsek S, Giles FJ, Quintás-Cardama A, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H. Verstovsek S, et al. Among authors: manley p. Leuk Res. 2006 Dec;30(12):1499-505. doi: 10.1016/j.leukres.2006.03.012. Epub 2006 May 8. Leuk Res. 2006. PMID: 16682077

4

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.

Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, Bhatia R. Konig H, et al. Among authors: manley p. Leukemia. 2008 Apr;22(4):748-55. doi: 10.1038/sj.leu.2405086. Epub 2008 Feb 14. Leukemia. 2008. PMID: 18273048

5

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T. White DL, et al. Among authors: manley pw. Blood. 2007 Dec 1;110(12):4064-72. doi: 10.1182/blood-2007-06-093617. Epub 2007 Aug 30. Blood. 2007. PMID: 17761829 Free article. Clinical Trial.

6

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H. Verstovsek S, et al. Among authors: manley p. Leuk Res. 2006 Nov;30(11):1365-70. doi: 10.1016/j.leukres.2006.04.005. Epub 2006 Jun 23. Leuk Res. 2006. PMID: 16797704

7

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP. White DL, et al. Among authors: manley p. Haematologica. 2012 Jun;97(6):907-14. doi: 10.3324/haematol.2011.056457. Epub 2011 Dec 29. Haematologica. 2012. PMID: 22207690 Free PMC article. Clinical Trial.

8

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Manley PW, Barys L, Cowan-Jacob SW. Manley PW, et al. Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458. Epub 2020 Sep 29. Leuk Res. 2020. PMID: 33096322 Review.

9

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. White DL, et al. Among authors: manley pw. Blood. 2006 Jul 15;108(2):697-704. doi: 10.1182/blood-2005-11-4687. Epub 2006 Apr 4. Blood. 2006. PMID: 16597591 Free article.

10

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Weisberg E, et al. Cancer Cell. 2005 Feb;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007. Cancer Cell. 2005. PMID: 15710326 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

356 results

Search Page

Filters